eLife9d
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer
This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...
Targeted Oncology22d
Controversy Swirls Around the Use of CDK4/6 Inhibitors as Adjuvant Breast Cancer Therapy
CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising ...
Targeted Oncology10d
The Targeted Pulse: Recent Approvals in Breast and Colorectal Cancers and the Controversy Over Adjuvant CDK4/6 Inhibitors in Breast Cancer
We also explore the controversy surrounding CDK4/6 inhibitors in adjuvant breast cancer therapy and discuss the MARIPOSA data for EGFR-mutated NSCLC. Dato-DXd Wins an FDA Approval for HR+/HER2– Breast ...
SurvivorNet20d
Verzenio is Significant & Cuts the Risk of Cancer Coming Back in Some Women With Early Breast Cancer A First For CDK4/6 Inhibitors
During a clinical trial, researchers found that CDK4/CDK6 inhibitor Verzenio may have a huge impact on women battling early stage breast cancer by decreasing the likelihood of the cancer returning.